LoginSignup
Imagen de perfil
Mona.Ohls ex Boersen.Bulle
@Boersen_Bulle
3Año·

Founded in 1992 in Martinsried near Munich, Germany, MorphoSys AG is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies in the areas of cancer and autoimmune diseases.


MorphoSys is advancing its proprietary pipeline of new drugs based on its leading expertise in antibody and protein technology.


The focus is on therapies in the field of oncology (benign and malignant tumor types as well as cancer). Based on its expertise in antibody, protein and peptide technologies.


Morphosys partner companies include the following international pharmaceutical companies: Bayer Pharma AG, Boehringer Ingelheim, Novartis AG, Johnson & Johnson, Merck & Co., Pfizer, Roche


Latest news: Morphosys announced in mid-October that its licensing partner Roche has received "breakthrough therapy" status for its Alzheimer's drug gantenerumab.


Current share price: € 39.15

Performance 3 years: -49.66

Performance 5 years: -5.33


Do you already know the German company?


---------------


Not an investment recommendation - Source: Wikipedia, deraktionaer

attachment
5
17 Comentarios
Imagen de perfil
Max@Max21
3Año
How do you see the company and the share price in the medium to long term?
•
1
•
Topper H.@TopperHarley
3Año
@Max21 As a rule, it does not respond; the channel is only used to offload content for the purpose of reach optimization.
•
2
•
Imagen de perfil
Max@Max21
3Año
@TopperHarley ok, good to know, then I'd better discuss it somewhere else 😂
•
1
•
Imagen de perfil
Mona.Ohls ex Boersen.Bulle@Boersen_Bulle
3Año
@TopperHarley Just stop spreading such nonsense again. I'm not on my cell phone 24/7 like you and I can't reply to "everything" either, otherwise I wouldn't have a private life anymore. Your hates, your negative mindset and your false claims towards me really get on my nerves, as they offer zero added value & you hide behind your anonymity and make fun of others.
You better focus on your stuff & your posts instead of me. Thanks ✌️
•
2
•
Imagen de perfil
Mona.Ohls ex Boersen.Bulle@Boersen_Bulle
3Año
@Max21 I personally find companies that are researching and developing in this area very interesting. Especially because of the cooperation with other large groups. From my point of view on the investment - it hasn't looked great in recent years... in 2000 the company was already at 106 euros and in 2001 again at 9.98 euros and it looked similar in 2020 and 2021. Due to the high fluctuations and the uncertainty "whether there will really be a breakthrough with a drug, therapy or vaccination" or whether there may even be side effects, not a long-term investment for me. And I use other companies for trades.

What do you think about the company? Are you invested?

(Not an investment recommendation, just my personal opinion).
•
2
•
Imagen de perfil
Max@Max21
3Año
@Boersen_Bulle I am also always very skeptical when there have been high fluctuations in the share price in the past.
I think the partnerships are very positive in themselves. However, the partnerships at Wirecard were also a given 😄
Even if Morphosys is not a "fraud" in my eyes. But results still have to be delivered.
If so, I would only invest a small risk position here in the long term.
•
2
•
Imagen de perfil
Mona.Ohls ex Boersen.Bulle@Boersen_Bulle
3Año
@Max21 Wirecard will remain in our memories forever 😬😵‍💫
•
1
•
Imagen de perfil
Max@Max21
3Año
@Boersen_Bulle definitively!
••
Imagen de perfil
Stefan@InvestmentPapa
3Año
Interesting to read, yes. But as a company, I didn't read it on the screen. I tend to be with the big global players when it comes to biotech and health. For me, the risk with the small companies is just too big. Morphosys has also made some strange decisions on the part of management in the past, after all. I don't need any turmoil in that respect, but thank you for the introduction.
•
1
•
Imagen de perfil
Mona.Ohls ex Boersen.Bulle@Boersen_Bulle
3Año
@InvestmentPapa Interesting! I didn't read about the management during my research. Thanks for the addition 👍 I'm also rather distanced!
••
Imagen de perfil
Alfred Wilhelm@GymTonic
3Año
Oh dear , the days of "Mr. Dausend" are long gone and quite definitely passé.
I had my first great profit-taking with this company...
Repeat attempts failed miserably ...
A prime example of a share that always goes one better when you think it can't go any lower ...
I'll take a look at it again at around 27 euros, it will still make it ...
•
1
•
Imagen de perfil
Mona.Ohls ex Boersen.Bulle@Boersen_Bulle
3Año
@GymTonic of course you don't forget the first big profit-taking 😬 when was that ? In the year 2019? Things didn't look so great after that... as you say, you think it can't go any lower but the company goes one better 😬🙈
••
Imagen de perfil
Alfred Wilhelm@GymTonic
3Año
@Boersen_Bulle my 2018 , I then went back in later and got out the second time in 2019 but the profit was no longer as big ... after that I was in again and got out with quite a big loss (I think about -35%) , since then I've kept my hands off the stock until it generates a really sustainable upward trend ...
••
Usuario eliminado
3Año
Comentario eliminado
Imagen de perfil
Mona.Ohls ex Boersen.Bulle@Boersen_Bulle
3Año
@Eochaid really not nice to look at in the long term. Were you able to take at least a few profits?
••
Ver una respuesta más
Usuario eliminado
3Año
Comentario eliminado
Imagen de perfil
Mona.Ohls ex Boersen.Bulle@Boersen_Bulle
3Año
@sonnenbrille I can understand 👍
••
Únase a la conversación
InscríbaseInicio de sesión